MX2019007574A - Metodos de tratamiento de sindrome de intestino irritable con formulaciones modificadas o de liberacion retardada de linaclotida. - Google Patents

Metodos de tratamiento de sindrome de intestino irritable con formulaciones modificadas o de liberacion retardada de linaclotida.

Info

Publication number
MX2019007574A
MX2019007574A MX2019007574A MX2019007574A MX2019007574A MX 2019007574 A MX2019007574 A MX 2019007574A MX 2019007574 A MX2019007574 A MX 2019007574A MX 2019007574 A MX2019007574 A MX 2019007574A MX 2019007574 A MX2019007574 A MX 2019007574A
Authority
MX
Mexico
Prior art keywords
linaclotide
delayed release
modified
methods
release formulations
Prior art date
Application number
MX2019007574A
Other languages
English (en)
Spanish (es)
Inventor
Hashash Ahmad
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of MX2019007574A publication Critical patent/MX2019007574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019007574A 2016-12-21 2017-12-21 Metodos de tratamiento de sindrome de intestino irritable con formulaciones modificadas o de liberacion retardada de linaclotida. MX2019007574A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437566P 2016-12-21 2016-12-21
PCT/US2017/067814 WO2018119191A1 (en) 2016-12-21 2017-12-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide

Publications (1)

Publication Number Publication Date
MX2019007574A true MX2019007574A (es) 2019-09-04

Family

ID=61022424

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007574A MX2019007574A (es) 2016-12-21 2017-12-21 Metodos de tratamiento de sindrome de intestino irritable con formulaciones modificadas o de liberacion retardada de linaclotida.
MX2023008839A MX2023008839A (es) 2016-12-21 2019-06-21 Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023008839A MX2023008839A (es) 2016-12-21 2019-06-21 Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.

Country Status (10)

Country Link
EP (1) EP3558337A1 (zh)
JP (2) JP2020512292A (zh)
CN (1) CN110475564A (zh)
AU (1) AU2017379082A1 (zh)
BR (1) BR112019012689A2 (zh)
CA (1) CA3048195A1 (zh)
EA (1) EA201991531A1 (zh)
MA (1) MA47112A (zh)
MX (2) MX2019007574A (zh)
WO (1) WO2018119191A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3979992A4 (en) * 2019-06-10 2023-09-13 Ironwood Pharmaceuticals, Inc. TREATMENT OF ABDOMINAL PAIN ASSOCIATED WITH DIARRHEA-DOMINANT IRGITABLE BOWEL SYSTEM
CA3238619A1 (en) * 2021-11-29 2023-06-01 Michael Gerber Pharmaceutical compositions for the treatment of visceral pain
WO2023196821A2 (en) * 2022-04-04 2023-10-12 Thomas Jefferson University Targeting neuropod cell gucy2c to control visceral pain and appetite

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
HUE049023T2 (hu) 2008-08-15 2020-08-28 Ironwood Pharmaceuticals Inc Linaklotidot tartalmazó, szájon át történõ beadásra szolgáló készítmények
WO2011020054A1 (en) * 2009-08-13 2011-02-17 Ironwood Pharmaceuticals Inc. Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
RS59978B1 (sr) * 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
DK2776055T3 (en) * 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
CA2898362C (en) * 2013-01-15 2020-09-01 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
ES2868873T3 (es) * 2015-06-05 2021-10-22 Ironwood Pharmaceuticals Inc Formulaciones de liberación modificada o dirigida de linaclotida

Also Published As

Publication number Publication date
CN110475564A (zh) 2019-11-19
WO2018119191A1 (en) 2018-06-28
JP2020512292A (ja) 2020-04-23
CA3048195A1 (en) 2018-06-28
MA47112A (fr) 2019-10-30
EP3558337A1 (en) 2019-10-30
AU2017379082A1 (en) 2019-07-04
BR112019012689A2 (pt) 2019-11-19
JP2022093472A (ja) 2022-06-23
EA201991531A1 (ru) 2019-11-29
MX2023008839A (es) 2023-08-14
WO2018119191A9 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2023010042A (es) Polinucleotidos moduladores.
MX2023008693A (es) Polinucleotidos moduladores.
MX2018005340A (es) Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos.
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
GB2541571A (en) Pharmaceutical compositions
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.
EA201791875A1 (ru) Комбинированная композиция тезофензина и бета-блокатора
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
MX2017013879A (es) Composiciones que comprenden anakinra.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.